Is Galmed Pharmaceuticals Ltd. (GLMD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 352.9% / 30% | 4.8% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 352.9% / 33% | 4.8% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 82.9% / 33% | 1.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 352.9% / 33% | 4.8% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 82.9% / 33% | 1.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -46.3% | |
| Return on Assets (ROA) | -20.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$6M |
| Free Cash Flow | -$6M |
| Total Debt | $0 |
| Current Ratio | 8.0 |
| Total Assets | $18M |
Price & Trading
| Last Close | $0.59 |
| 50-Day MA | $0.65 |
| 200-Day MA | $1.20 |
| Avg Volume | 61K |
| Beta | 0.4 |
|
52-Week Range
$0.41
| |
About Galmed Pharmaceuticals Ltd. (GLMD)
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Galmed Pharmaceuticals Ltd. (GLMD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Galmed Pharmaceuticals Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Galmed Pharmaceuticals Ltd.'s debt ratio?
Galmed Pharmaceuticals Ltd.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Galmed Pharmaceuticals Ltd.'s key financial metrics?
Galmed Pharmaceuticals Ltd. has a market capitalization of $3M. Return on equity stands at -46.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.